Pliant Therapeutics (PLRX)
(Real Time Quote from BATS)
$13.51 USD
+0.06 (0.45%)
Updated Aug 26, 2024 01:32 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Pliant Therapeutics, Inc. [PLRX]
Reports for Purchase
Showing records 1 - 20 ( 33 total )
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Once Again 320 mg PSC Data Encouraging But Confounded by Inconsistencies
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EASL Posters Further Inform Bexotegrast''s Potential in PSC
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Collagen PET Data on Bexotegrast Further Supports Potential Fibrosis Reversal, Lower Cough Severity in IPF
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q Recap: BEACON-IPF Phase 2b Portion Complete Enrollment in 1Q25
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap; Phase 2b BEACON-IPF Trial Continues Enrollment; Week 24 INTEGRIS-PSC Data on Target in Mid-2024; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bexotegrast Shows Promise in PSC But the Road Ahead Is Far From Clear; Key Value Proposition Remains IPF; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
320 mg Dose Effect in PSC Remains Positive Across Multiple Endpoints, but ELF Score Is Confounding; Trim PT to $48
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap; We Look For Late-Breaker at The Liver Meeting 2023 For Additional Data From INTEGRIS-PSC Study; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SITC Presentations Outline Rationale For PLN-101095''s Dual Inhibition of Integrins ava8/ava1 in Oncology
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Interim 12-Week Data From INTEGRIS-PSC Highly Encouraging and Better Than Expected; Raise PT to $52
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bexotegrast''s Potential in IPF Highlighted in ERS International Congress 2023; P2a INTEGRIS-PSC Data in 3Q; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q Recap; Phase 2b BEACON-IPF Trial Kicks Off; Phase 2a INTEGRIS-PSC Data This Quarter; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fibrogen''s Pamrevlumab Exits the IPF Race With Phase 3 Miss; EASL Presentations Highlight Bexotegrast in PSC; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bexotegrast''s Potential in IPF Highlighted at ATS 2023; Phase 2b BEACON-IPF to Start in Mid-2023 Start; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q Recap: Phase 2b BEACON-IPF Study to Start Mid-2023; Initial 12-Week Data in PSC in 3Q23; Moderate PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Additional Data From Phase 2a INTEGRIS-IPF Study Further Highlights Bexotegrast''s Potential in IPF; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bexotegrast 320 mg Demonstrates Durable Improvements in FVC, QLF and Cough at 24 Weeks; PT Nudged Up to $55
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
American Thoracic Society International Conference Presentations Highlight Bexotegrast''s Potential in IPF; Affirm Buy.
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Final Bexotegrast 320 mg Data Could Positively Surprise Again; Phase 2b IPF Trial Starts Mid-2023; Affirm Buy, PT to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Pliant Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap: Data for 320 mg Dose in IPF in Early 1Q23; PSC Data in 3Q23; PLN-101095 to Enter the Clinic; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E